Mwandishi:
Dkt. Mercy M, CO
Mhariri:
Dkt. Mangwella S, MD
Sildenafil ni moja kati ya dawa inayotumika kutibu matatizo ya kushindwa kusimamisha uume au kusimamisha kwa muda mfupi na kushusha shinikizo la la juu la damu kwenys mapafudamu iliyojuu kwenye mapafu.
Majina ya kibiashara
Majina mengine ya kibiashara ya sildenafil ni;
Revatio
Viagra
Sildenafil ipo kundi gani la dawa?
Sildenafil ni dawa iliyo katika kundi la PAH, PDE-5 Inhibitors; Phosphodiesterase-5 Enzyme Inhibitors.
Dawa zilizo kundi moja na Sildenafil
Dawa zilizo kundi moja na Sildenafil ni ;
Vardenafil
Tadalafil
Avanafil
Fomu ya Sildenafil
Dawa hii ipo katika fomu ya;
Kidonge
Solusheni kwaajiri ya sindano
Solusheni kwaajiri ya kunywa
Uzito wa Sildenafil
Sildenafil ina uzito ufuatao;
Vidonge (Revatio)
20mg
Vidonge (Viagra)
25mg
50mg
100mg
Solusheni kwaajiri ya sindano
10mg/12.5ml
Kimiminika cha kunywa
10mg/ml
Sildenafil hutibu nini?
Hutumika kutibu matatizo kwa wanaume wasio na uwezo wa kusimamisha uume kwa muda mrefu
Hutumika kutibu shinikizo la damu iliyojuu kwenye mapafu.
Namna Sildenafil inavyoweza kufanya kazi
Sildenafil hufanya kazi ya kuzuia PDE-5 hivyo kuongeza cyclic guanosine monophosphate cGMP na kuruhusu mishipa iweze kutanuka.
Ufyozwaji wa dawa
Ufyozwaji wa dawa hii hufanyika vizuri kwenye mfumo wa chakula, kiwango cha dawa kinachoonekana kwenye damu baada ya kutumia ni 40% na huanza kuonekana kwenye damu ndani ya dakika 30-120 baada ya mtu kumeza dawa.
Mwingiliano wa Sildenafil na chakula
Dawa hii inaweza kutumika mtu akiwa amepata chakula au akiwa hajapata chakula.
Wagonjwa wasiopaswa kutumia Sildenafil
Wagonjwa wenye mzio wa Sildenafil.
Wagonjwa wenye mzio wa dawa jamii ya PDE-5 Inhibitors; Phosphodiesterase-5 Enzyme inhibitors.
Utoaji taka wa Saldenafil mwilini
Asilimia themanini (80%) ya dawa hii hutolewa kwa njia ya haja kubwa na asilimia kumi na tatu (13%) hutolewa kwa njia ya mkojo.
Matumizi ya Sildenafil kwa mama mjamzito
Hakuna tafiti zinazoonesha madhara ya dawa hii kwa mama mjamzito lakini mwanamke mwenye matatizo ya moyo asipotibiwa anaweza anakuwa kwenye hatari ya kujifungua kabla ya muda pia mama kuwa kwenye hatari ya kifo.
Matumizi ya Sildenafil kwa mama anayenyonyesha
Hakuna tafiti zinazoonesha kuwa dawa hii inaweza kuleta madhara kwa mama anayenyonysha, kwa mtoto anayenyosha na katika uzalishwaji wa maziwa.
Dawa zenye muingiliano na Sildenafil
Dawa zenye mwingiliano mkali na hivyo kutofaa kutumika pamoja na Sildenafil
Abametapir
Alfuzosin
Amyl nitrite
Apalutamide
Asenapine
Chloramphenicol
Clarithromycin
Conivaptan
Crizotinib
Dabrafenib
Doxazosin
Eslicarbazepine acetate
Fexinidazole
Glyceryl trinitrate pr
Ivosidenib
Ketoconazole
Lonafarnib
Lopinavir
Mifepristone
Mitotane
Nafcillin
Ombitasvir/paritaprevir/ritonavir & dasabuvir
Oxcarbazepine
Pentobarbital
Phenobarbital
Phenoxybenzamine
Phentolamine
Phenytoin
Prazosin
Primidone
Ritonavir
Silodosin
St john's wort
Terazosin
Tucatinib
Voxelotor
Dawa zinazoweza kutumika na Sildenafil chini ya uangalizi
Acebutolol
Amifostine
Artemether/lumefantrine
Atenolol
Benazepril
Captopril
Carbamazepine
Carvedilol
Cenobamate
Cimetidine
Cyclosporine
Darunavir
Deferasirox
Dexamethasone
Efavirenz
Epoprostenol
Erythromycin base
Griseofulvin
Idelalisib
Iloperidone
Indinavir
Isoniazid
Istradefylline
Itraconazole
Labetalol
Lapatinib
Lesinurad
Letermovir
Levamlodipine
Lorlatinib
Maraviroc
Metoprolol
Miconazole vaginal
Nebivolol
Nefazodone
Nevirapine
Nifedipine
Nilotinib
Nitroprusside sodium
Penbutolol
Pindolol
Posaconazole
Propranolol
Ribociclib
Rifabutin
Rifampin
Voriconazole
Dawa zenye mwingiliano mdogo na Sildenafil;
Labetalol
Macitentan
Sapropterin
Maudhi madogo ya Sildenafil
Maumivu ya kichwa
kichefuchefu
Kutokwa na jasho
Kukosa usingizi
Kutokwa damu puani
Kiungulia
Kizunguzungu
Wekundu kwenyengozi
Kuharisha
kizunguzungu
Vipele kwenye ngozi
Ufanye nini endapo utasahau kutumia dozi yako?
Ni muhimu sana kutumia dozi yako kwa wakati sahihi.Kama umesahau kutumia dozi yako kwa wakati sahihi wasiliana na daktari wako au mfamasia akupe maelekezo ya dozi inayofuata.
13 Juni 2023 19:18:46
Dawa Sildenafil
Imeboreshwa,
30 Oktoba 2021 18:29:27
Dawa yoyote ni sumu, usitumie dawa pasipo ushauri wa daktari kuepuka madhara kwenye ogani mbalimbali kama figo na ini. Matumizi ya dawa pasipo ushauri wa daktari unaweza kusababisha madhara na usugu wa vimelea vya maradhi kwenye dawa.
ULY CLINIC inakushauri siku zote uwasiliane na daktari wako kwa ushauri na tiba kabla ya kuchukua hatua yoyote ile baad aya kusoma makala hii.
Kupata ushauri zaidi na tiba kutoka kwa daktari wa ULY CLINIC bofya Mawasiliano yetu au Pata tiba.
Rejea za mada hii:
Bäck SE, et al. Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab Invest. 1989 Nov;49(7):641–646.
Bax RP, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):311–320.
Burman LA, et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991 Feb;27(2):219–224.
Christensson BA, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532–1537.
DAVIES DF, SHOCK NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950 May;29(5):496–507.
Douglas JG, et al. The pharmacokinetics of cefuroxime in the elderly. J Antimicrob Chemother. 1980 Jul;6(4):543–549.
Granerus G, et al. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest. 1981 Oct;41(6):611–616.
Harrison MP, et al. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):265–277.
Jones RN, et al. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):9–29.
Krutzén E, et al. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 1984 Dec;104(6):955–961.
Ljungberg B, et al. Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis. 1987 Mar-Apr;9(2):250–264.